Wei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Chen has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Shourong Liu
Hangzhou Xixi Hospital, Hangzhou, China
2 shared publications - Tingting Shi
The Third Affiliated Hospital of Zhejiang Chinese Medical University
1 shared publication - Xi Zou
The Third Affiliated Hospital of Zhejiang Chinese Medical University
1 shared publication - Yidan Shao
The Third Affiliated Hospital of Zhejiang Chinese Medical University
1 shared publication - Yunling Ke
Department of Pharmaceutical Preparation, The Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 17 February 2026
- Published by Elsevier in Journal of the Formosan Medical Association
Comment on “Far-infrared therapy improves cardiovascular and infectious outcomes in peritoneal dialysis patients”
- 17 February 2026
- Published by Elsevier in Journal of the Formosan Medical Association
Open AccessComment on “Far-infrared therapy improves cardiovascular and infectious outcomes in peritoneal dialysis patients”
- Open Access
- 29 December 2025
- Published by Wiley
Efficacy of Glycyrrhizic Acid Preparations in Severe or Critical COVID-19 Patients: A Retrospective Observational Study
Background/Aims Glycyrrhizic acid (GA) has shown therapeutic potential in patients with mild COVID-19; however, its applicability in severe and critical patients needs more substantial evidence. This study aimed to evaluate the clinical effectiveness of GA in this patient population and to explore whether prolonged treatment confers additional benefits. Methods This retrospective study enrolled 73 patients with severe or critical COVID-19. According to their exposure to GA therapy, patients were divided into an observation group (received GA therapy) and a control group (did not receive GA therapy). The primary outcome was in-hospital all-cause mortality. Survival differences were compared using Kaplan–Meier analysis, and a multivariate logistic regression model was further employed to identify independent predictors of mortality. Results The all-cause mortality during hospitalization was significantly lower in the observation group than in the control group (P = 0.005), with survival curves also demonstrating a significant difference (P = 0.039). Patients in the observation group also had significantly shorter durations of corticosteroid use and median hospital stays among survivors. By hospital day 14 or at discharge, the observation group exhibited more pronounced improvements in inflammatory markers and a higher rate of improvement on lung CT imaging. In a subgroup analysis of patients who received GA therapy, the long-course group showed lower mortality than the short-course group (10.71% vs. 27.78%), although this difference did not reach statistical significance (P = 0.059). However, the difference in survival curves between these two subgroups reached borderline statistical significance (P = 0.051). Multivariate regression analysis identified non-receipt of GA therapy as an independent risk factor for mortality. Conclusion GA therapy may confer benefits in delaying disease progression and reducing mortality, potentially through its antiviral, anti-inflammatory, and corticosteroid-sparing effects. Extending the treatment course or increasing the dosage could be viable strategies to enhance efficacy, although these approaches require validation in larger prospective studies.
- 29 December 2025
- Published by Wiley
Open AccessEfficacy of Glycyrrhizic Acid Preparations in Severe or Critical COVID-19 Patients: A Retrospective Observational Study
Background/Aims Glycyrrhizic acid (GA) has shown therapeutic potential in patients with mild COVID-19; however, its applicability in severe and critical patients needs more substantial evidence. This study aimed to evaluate the clinical effectiveness of GA in this patient population and to explore whether prolonged treatment confers additional benefits. Methods This retrospective study enrolled 73 patients with severe or critical COVID-19. According to their exposure to GA therapy, patients were divided into an observation group (received GA therapy) and a control group (did not receive GA therapy). The primary outcome was in-hospital all-cause mortality. Survival differences were compared using Kaplan–Meier analysis, and a multivariate logistic regression model was further employed to identify independent predictors of mortality. Results The all-cause mortality during hospitalization was significantly lower in the observation group than in the control group (P = 0.005), with survival curves also demonstrating a significant difference (P = 0.039). Patients in the observation group also had significantly shorter durations of corticosteroid use and median hospital stays among survivors. By hospital day 14 or at discharge, the observation group exhibited more pronounced improvements in inflammatory markers and a higher rate of improvement on lung CT imaging. In a subgroup analysis of patients who received GA therapy, the long-course group showed lower mortality than the short-course group (10.71% vs. 27.78%), although this difference did not reach statistical significance (P = 0.059). However, the difference in survival curves between these two subgroups reached borderline statistical significance (P = 0.051). Multivariate regression analysis identified non-receipt of GA therapy as an independent risk factor for mortality. Conclusion GA therapy may confer benefits in delaying disease progression and reducing mortality, potentially through its antiviral, anti-inflammatory, and corticosteroid-sparing effects. Extending the treatment course or increasing the dosage could be viable strategies to enhance efficacy, although these approaches require validation in larger prospective studies.
- Open Access
- 1 January 2025
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2025 (1)
Rabdosia rubescens Inhibits CYP7A1 Expression and Induces Autophagy to Reduce Alcohol‐Induced Liver Damage in Mice
Objective: Investigating the antialcoholic liver injury properties of Rabdosia rubescens and its effect on the expression of CYP7A1 and levels of autophagy. Materials and Methods: Male C57BL/6 mice were randomly divided into three groups, namely, the control group (Lieber–DeCarli standard diet), model group (Lieber–DeCarli ethanol diet), and treatment group ( Rabdosia rubescens at concentrations of 50 mg/kg, 100 mg/kg, and 200 mg/kg). The mice were fed their respective diets for 10 days, with the treatment group receiving the corresponding concentration of Rabdosia rubescens . On the 11th day, all the mice except those in the control group were given 30% EtOH. Nine hours later, the mice were sacrificed and their blood serum and liver tissue were collected for analysis. The effect of Rabdosia rubescens on alcohol‐induced liver damage was evaluated by testing serum biochemical indicators, liver bile acid content, liver tissue histopathological changes, liver LC3 and p62 immunohistochemical staining, liver inflammatory factors, and CYP7A1, SREBP, FAS, LC3, Beclin‐1, ATG7, and p62 expressions. Results: Compared with the model group, Rabdosia rubescens was found to significantly reduce the levels of ALT, AST, TG, TC, and TBA in the serum of mice with alcoholic liver injury ( p < 0.05 or p < 0.01). Rabdosia rubescens was found to significantly reduce the level of apoptosis in H&E‐stained liver tissue sections. Rabdosia rubescens also significantly reduced the levels of TNF‐α and IL‐1β in the livers of mice ( p < 0.001). Rabdosia rubescens was found to induce the expression of LC3, Beclin‐1, and ATG7 proteins and mRNA, while inhibiting the expression of CYP7A1, SREBP, FAS, and p62 proteins and mRNA ( p < 0.05 or p < 0.01). Conclusion: Rabdosia rubescens has been shown to relieve alcohol‐induced liver damage in mice by reducing levels of CYP7A1, alleviating cholestasis and reducing inflammation. It can also reduce alcohol‐induced liver damage by decreasing fat synthesis and inducing autophagy.
- 1 January 2025
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2025 (1)
Open AccessRabdosia rubescens Inhibits CYP7A1 Expression and Induces Autophagy to Reduce Alcohol‐Induced Liver Damage in Mice
Objective: Investigating the antialcoholic liver injury properties of Rabdosia rubescens and its effect on the expression of CYP7A1 and levels of autophagy. Materials and Methods: Male C57BL/6 mice were randomly divided into three groups, namely, the control group (Lieber–DeCarli standard diet), model group (Lieber–DeCarli ethanol diet), and treatment group ( Rabdosia rubescens at concentrations of 50 mg/kg, 100 mg/kg, and 200 mg/kg). The mice were fed their respective diets for 10 days, with the treatment group receiving the corresponding concentration of Rabdosia rubescens . On the 11th day, all the mice except those in the control group were given 30% EtOH. Nine hours later, the mice were sacrificed and their blood serum and liver tissue were collected for analysis. The effect of Rabdosia rubescens on alcohol‐induced liver damage was evaluated by testing serum biochemical indicators, liver bile acid content, liver tissue histopathological changes, liver LC3 and p62 immunohistochemical staining, liver inflammatory factors, and CYP7A1, SREBP, FAS, LC3, Beclin‐1, ATG7, and p62 expressions. Results: Compared with the model group, Rabdosia rubescens was found to significantly reduce the levels of ALT, AST, TG, TC, and TBA in the serum of mice with alcoholic liver injury ( p < 0.05 or p < 0.01). Rabdosia rubescens was found to significantly reduce the level of apoptosis in H&E‐stained liver tissue sections. Rabdosia rubescens also significantly reduced the levels of TNF‐α and IL‐1β in the livers of mice ( p < 0.001). Rabdosia rubescens was found to induce the expression of LC3, Beclin‐1, and ATG7 proteins and mRNA, while inhibiting the expression of CYP7A1, SREBP, FAS, and p62 proteins and mRNA ( p < 0.05 or p < 0.01). Conclusion: Rabdosia rubescens has been shown to relieve alcohol‐induced liver damage in mice by reducing levels of CYP7A1, alleviating cholestasis and reducing inflammation. It can also reduce alcohol‐induced liver damage by decreasing fat synthesis and inducing autophagy.